Angana Mukherjee

Angana Mukherjee

Auto-generated profile, based on publicly available information

Angana Mukherjee

Department of Biological Sciences, University of Notre Dame

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in mBio
Verified
Journal Article
Open access
AMAngana Mukherjee
Angana Mukherjee
MCMarie-Ève Crochetière
Marie-Ève Crochetière
ASAudrey Sergerie
Audrey Sergerie
SASouad Amiar
Souad Amiar
LTL. Alexa Thompson
L. Alexa Thompson
DRDave Richard
Dave Richard
Malaria represents an enormous burden for a significant proportion of humanity and the lack of vaccines and problems with drug resistance to all antimalarials demonstrate the need to develop new therapeutics. Inhibitors of phosphoinositide metabolism are currently being developed as antimalarials but our understanding of this biological pathway is incomplete.

17 July 2024 in mBio
Verified
Journal Article
Open access
JKJohn Kane
John Kane
XLXue Li
Xue Li
SKSudhir Kumar
Sudhir Kumar
KBKatrina A Button-Simons
Katrina A Button-Simons
KBKatelyn M. Vendrely Brenneman
Katelyn M. Vendrely Brenneman
MFMichael T. Ferdig
Michael T. Ferdig
Piperaquine (PPQ) is widely used in combination with dihydroartemisinin as a first-line treatment against malaria. Multiple genetic drivers of PPQ resistance have been reported, including mutations in the Plasmodium falciparum chloroquine resistance transporter ( pfcrt ) and increased copies of plasmepsin II/III ( pm2/3 ). We generated a cross between a Cambodia-derived multidrug-resistant KEL1/PLA1 lineage isolate (KH004) and a drug-susceptible Malawian parasite (Mal31). Mal31 harbors a wild-type (3D7-like) pfcrt allele and a single copy of pm2/3 , while KH004 has a chloroquine-resistant (Dd2-like) pfcrt allele with an additional G367C substitution and multiple copies of pm2/3 . We recovered 104 unique recombinant parasites and examined a targeted set of progeny representing all possible combinations of variants at pfcrt and pm2/3 . We performed a detailed analysis of competitive fitness and a range of PPQ susceptibility phenotypes with these progenies, including PPQ survival assay, area under the dose response curve, and a limited point IC 50 . We find that inheritance of the KH004 pfcrt allele is required for reduced PPQ sensitivity, whereas copy number variation in pm2/3 further decreases susceptibility but does not confer resistance in the absence of additional mutations in pfcrt . A deep investigation of genotype-phenotype relationships demonstrates that progeny clones from experimental crosses can be used to understand the relative contributions of pfcrt , pm2/3 , and parasite genetic background to a range of PPQ-related traits. Additionally, we find that the resistance phenotype associated with parasites inheriting the G367C substitution in pfcrt is consistent with previously validated PPQ resistance mutations in this transporter. IMPORTANCE: Resistance to piperaquine, used in combination with dihydroartemisinin, has emerged in Cambodia and threatens to spread to other malaria-endemic regions. Understanding the causal mutations of drug resistance and their impact on parasite fitness is critical for surveillance and intervention and can also reveal new avenues to limiting the evolution and spread of drug resistance. An experimental genetic cross is a powerful tool for pinpointing the genetic determinants of key drug resistance and fitness phenotypes and has the distinct advantage of quantifying the effects of naturally evolved genetic variation. Our study was strengthened since the full range of copies of KH004 pm2/3 was inherited among the progeny clones, allowing us to directly test the role of the pm2/3 copy number on resistance-related phenotypes in the context of a unique pfcrt allele. Our multigene model suggests an important role for both loci in the evolution of this multidrug-resistant parasite lineage.

22 February 2022 in mBio
Verified
Journal Article
Open access
MNMaisha Khair Nima
Maisha Khair Nima
AMAngana Mukherjee
Angana Mukherjee
SSSaiful Arefeen Sazed
Saiful Arefeen Sazed
MHMuhammad Riadul Haque Hossainey
Muhammad Riadul Haque Hossainey
CPChing Swe Phru
Ching Swe Phru
KHKasturi Haldar
Kasturi Haldar
Malaria elimination is a Millennium Development Goal. Artemisinins, fast-acting antimalarial drugs, have played a key role in malaria elimination.

25 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMaisha Khair Nima
Maisha Khair Nima
NBNirjhar Bhattacharyya
Nirjhar Bhattacharyya
JPJungyoon Park
Jungyoon Park
DSDouglas Shoue
Douglas Shoue
CPChing Swe Phru
Ching Swe Phru
AMAngana Mukherjee
Angana Mukherjee
Artemisinin partial resistance (ArtR), mediated by Kelch13 (K13) gene mutations in Plasmodium falciparum , has caused delayed parasite clearance and, together with partner drug resistance, treatment failures in the Greater Mekong Subregion (GMS). The Chittagong Hill Tracts (CHTs), located in southeastern Bangladesh and bordering Myanmar and India, regions with prevalent K13 mutations, account for approximately 90% of the country’s malaria infections but have not yet reported ArtR-causing K13 mutations. Importantly, however, some isolates from the CHTs have demonstrated moderate in vitro ArtR in the absence of K13 mutations. To assess the potential threat of K13-mediated ArtR in Bangladesh, we proactively evaluated the impact of three prevalent neighboring K13 mutations (F446I, R561H, and C580Y) on ArtR and parasite fitness in parasites isolated from the CHTs. We edited these mutations into two distinct genetic backgrounds: an artemisinin-sensitive strain (CHT-S) and a K13-independent, moderately resistant strain (CHT-R). In these edited lines, we then evaluated ArtR levels and fitness using ring-stage survival assays (RSA), post-drug treatment recovery assays, and competitive fitness assays against isogenic control strains. Prior to genome editing, both isolates were characterized for baseline drug susceptibility, resistance-associated mutations, and population structure. We found that C580Y and R561H mutations, but not F446I, confer increased in vitro ArtR in the CHT-R background already exhibiting K13-independent moderate resistance. All three mutations incurred minimal or no fitness costs in both genetic backgrounds. Notably, R561H, the dominant allele at the Thai-Myanmar border and currently expanding in Rwanda, mediates extreme resistance in the CHT-R background, with mean RSA survival rates of 30.9±1.9%, an unprecedented resistance level among K13-engineered lines. R561H also showed fitness advantages (0.5% per generation) and the highest growth recovery post-treatment. This represents the first experimental study modeling this K13 mediated ArtR risk in Bangladeshi parasites. In conclusion, we found that indigenous P. falciparum isolates in the CHTs possess inherent genetic potential to sustain high-level ArtR and fitness advantages if K13 mutations emerge, raising urgent concerns for containment and surveillance strategies during Bangladesh’s malaria elimination phase.

8 April 2026 in mBio
Verified
Journal Article
Open access
MNMaisha Khair Nima
Maisha Khair Nima
NBNirjhar Bhattacharyya
Nirjhar Bhattacharyya
DSDouglas Shoue
Douglas Shoue
JPJungyoon Park
Jungyoon Park
CPChing Swe Phru
Ching Swe Phru
AMAngana Mukherjee
Angana Mukherjee
Artemisinin partial resistance (ART-R), driven by mutations in the Plasmodium falciparum kelch13 ( k13 ) gene, has contributed to malaria treatment failures in the Greater Mekong Subregion (GMS). The Chittagong Hill Tracts (CHTs) of Bangladesh account for nearly 90% of national malaria cases. Although K13-mediated ART-R has not been reported in the CHTs, its emergence remains a concern due to the region’s proximity to K13-mutation-endemic areas in Myanmar and India, and the presence of moderate K13-independent ART-R. A meta-analysis of global K13 mutation frequency identified C580Y, F446I, and R561H as the most prevalent substitutions, particularly in the GMS. To evaluate their potential impact, we introduced these mutations into two recent CHT isolates via CRISPR-Cas9: an artemisinin-sensitive strain and a moderately in vitro resistant, K13-independent strain (CHT-R). Edited lines were phenotyped using ring-stage survival assays (RSAs), post-treatment recovery, and competitive fitness assays. C580Y and R561H conferred marked increases in ART-R in both strains, while F446I had only a modest effect in CHT-R. All three mutations incurred minimal asexual fitness costs, except for F446I in the CHT-R background. R561H, the dominant allele at the Thai-Myanmar border and now expanding in Rwanda, conferred extreme resistance in CHT-R (RSA: 30.09% ± 1.9%), alongside an asexual growth advantage (fitness: 5.1% per generation) and the highest post-treatment recovery. This work provides the first functional evidence from South Asian parasites, including the first Asian analysis of K13 mutations in a resistant background, demonstrating that CHT parasites are genetically primed to sustain high-level ART-R, warranting enhanced surveillance during Bangladesh’s malaria elimination phase. IMPORTANCE: Artemisinin resistance threatens global malaria control and elimination efforts. While the Greater Mekong Subregion is already entrenched with kelch13 (K13)-mediated resistance, Bangladesh, though not yet reporting K13 mutations, has confirmed K13-independent artemisinin resistance in its endemic Chittagong Hill Tracts, which border resistance hotspots in Myanmar. This study is the first to functionally test globally dominant K13 mutations in Bangladeshi Plasmodium falciparum using genome editing. We show that mutations such as R561H and C580Y significantly increase resistance and asexual fitness, particularly in strains already carrying K13-independent resistance. These findings suggest that local parasites are genetically primed to acquire and sustain high-level resistance in asexual stages if these mutations emerge. Our work provides a timely warning and a framework for assessing drug resistance risk in other low-transmission regions with ongoing artemisinin use, critical for national elimination programs and global efforts to prevent the spread of resistance beyond Southeast Asia.

7 October 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
AMAngana Mukherjee
Angana Mukherjee
AAAshenafi Bahita Assefa
Ashenafi Bahita Assefa
CTChristopher V. Turlo
Christopher V. Turlo
LNLisa Checkley Needham
Lisa Checkley Needham
DSDouglas Shoue
Douglas Shoue
JBJeffrey A. Bailey
Jeffrey A. Bailey
Recent genomic investigation in Ethiopia identified the first detection of the Plasmodium falciparum Kelch13 (K13) C580Y substitution in the Horn of Africa. To assess its functional impact, we introduced C580Y into two recently collected Ethiopian clinical isolates using CRISPR-Cas9 genome editing. Ring-stage survival assays showed significantly elevated in vitro dihydroartemisinin survival in edited parasites relative to isogenic controls, demonstrating that C580Y confers artemisinin tolerance in contemporary Ethiopian parasite genetic backgrounds.